The chief technology officer and co-founder explained the technology and design choices that went into Biolinq’s device, which he hopes will be easier to use than other glucose monitors.
Biolinq’s Jared Tangney on making CGMs unintimidating Read More »
The 982 HHS employees who received reduction-in-force notices are not represented by the unions that are plaintiffs in the case, the department’s head of personnel argued in a court filing.
HHS says it can still fire workers despite judge’s order pausing shutdown layoffs Read More »
In comments submitted to the Trump administration on its medical equipment investigation, the industry group recommended a tariff-free trading bloc with trusted countries among its proposals.
AdvaMed calls for series of trade actions in response to Section 232 probe Read More »
The company has received approval to validate and define the feature in a study that is scheduled to start this year.
Ōura to pursue FDA clearance of blood pressure feature for smart ring Read More »
The 982 HHS employees who received reduction-in-force notices are not represented by the unions that are plaintiffs in the case, the department’s head of personnel argued in a court filing.
HHS says it can still fire workers despite judge’s order pausing shutdown layoffs Read More »
The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting mechanism of action gives it activity in improving kidney conditions in patients with lupus nephritis.
Roche’s Gazyva Expands Out of Cancer With FDA Approval for Lupus Read More »
Cost Plus Drugs is sharing pricing data with TrumpRx, the administration’s new direct-to-consumer prescription drug website set to launch next year.
Mark Cuban says Cost Plus Drugs will partner with TrumpRx Read More »
The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.
Dexcom faces proposed class action suit over G7 CGM problems Read More »
Last month, investors’ hopes were dashed as Replimune suggested alignment had not yet been reached with the FDA on RP1’s future. Now, the regulator has accepted a refiled application after all.
Replimune Soars Upon FDA Resubmission for Advanced Melanoma Drug Read More »
Ivonescimab’s progression-free survival data in non-small cell lung cancer bode well for an upcoming overall survival readout, according to Truist analysts, who noted that “OS is likely to be statistically significant” in favor of the PD-1/VEGF bispecific.
